Drug: Torisel (temsirolimus)
Indication: Renal cell carcinoma
Company: Wyeth
Approval Date: May 30, 2007
Scoop: Torisel is an mTOR inhibitor. In in vitro studies using cancer cells, mTOR inhibition blocked the translation of genes that regulate the cell cycle. Torisel improved median overall survival by 49 percent in Phase III compared to interferon-alpha.
More news:
FDA approves Wyeth's Torisel. Report
Wyeth looking for Torisel approvals. Report
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2010 FierceMarkets. All rights reserved. |
 |
SHARE
WITH: